Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
While the MET pathway is significant in predicting gastrointestinal (GI) cancers, it is a redundant pathway, said Shah. There are many ways to activate the pathways and increase pro-survival signaling, such as through EGFR, HER2 or IGFR, according to Shah.